See What HealthDay Can Do For You
Contact Us

Meta-Analysis Shows 8 SNPs Tied to Metabolic Syndrome

SNPs linked to metabolic syndrome are mostly located in genes involved in lipid metabolism

MONDAY, July 25 (HealthDay News) -- Eight single nucleotide polymorphisms (SNPs) are associated with metabolic syndrome (MetS), mostly located in genes involved in dyslipidemia, according to a meta-analysis published online July 12 in Obesity Reviews.

C.M. Povel, from the National Institute for Public Health and the Environment in Bilthoven, Netherlands, and colleagues reviewed available literature up to June 2010 to investigate the association between SNPs and MetS. A total of 88 studies on 25 genes with at least one SNP-MetS association were analyzed for an accumulative population of 4,000 or more participants. SNPs for which data were available from three or more studies in a generally healthy population were chosen for meta-analysis. Additional meta-analyses were conducted for nine SNPs in seven genes, including GNB3, PPARG, TCF7L2, APOA5, APOC3, APOE, CETP.

The investigators identified an association between MetS and eight SNPs, mostly located in the genes involved in lipid metabolism. In individuals with MetS, minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3), and 174G>C (IL6) were more prevalent. In individuals with MetS, the minor allele of Taq-1B (CETP) was less prevalent.

"We found evidence for an association with MetS for eight SNPs. All of these SNPs were also associated with an individual MetS feature, most of them with dyslipidemia," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.